Plantimex Recalls Mamisan Lidocaine Ointment Containers Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child-Resistant Packaging
| Source | US CPSC (Consumer Products) |
|---|---|
| Category | Consumer Product |
| Severity | Unclassified |
| Status | unknown |
| Recall date | December 18, 2025 |
| Reported | December 18, 2025 |
| Recalling firm | MiramarLab, of Doral, Florida |
| Country / region | United States |
Hazard
The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.
Product description
This recall involves Mamisan Pain Relieving Topical Ointment jars. The ointment comes in an orange container with a white continuous thread lid and has the Mamisan trademark printed on top of the lid and on the label. The ointment was sold in a 3.52 ounce plastic jar. The wraparound label includes instructions and drug facts. Only jars with UPC code 860006498115 are included in the recall.
Remedy
Consumers should immediately secure the recalled ointment jars out of the sight and reach of children and contact Plantimex to receive a free replacement lid. Once the product is secured with the replacement lid, consumers can use the product, as directed.
Affected products
- Mamisan Pain Relieving Topical Ointment
Official source: US CPSC (Consumer Products) notice ↗